Wealthfront Advisers
ALXN

Wealthfront Advisers’s Alexion Pharmaceuticals ALXN Stock Holding History

Wealthfront Advisers’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,269
Closed -$1.15M – 716
2021
Q2 		$1.15M Buy
6,269
+1,598
+34% +$274K 0.01% 412
2021
Q1 		$714K Buy
4,671
+917
+24% +$142K ﹤0.01% 416
2020
Q4 		$587K Buy
3,754
+370
+11% +$47.5K ﹤0.01% 416
2020
Q3 		$387K Buy
3,384
+224
+7% +$24.2K ﹤0.01% 432
2020
Q2 		$355K Buy
+3,160
New +$335K ﹤0.01% 432
2019
Q3 		– Sell
-2,113
Closed -$277K – 496
2019
Q2 		$277K Sell
2,113
-679
-24% -$87.5K ﹤0.01% 448
2019
Q1 		$377K Buy
+2,792
New +$347K ﹤0.01% 403

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Wealthfront Advisers's ALXN Position: Q3 2021 in Review

Wealthfront Advisers sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 6,269 shares — an estimated $1.15M sold.

Wealthfront Advisers first reported a position in ALXN in Q1 2019 and held it in 7 quarters. The position peaked at $1.15M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Wealthfront Advisers reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Wealthfront Advisers sold 6,269 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.15M.
  • Wealthfront Advisers first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 7 quarters.
  • Wealthfront Advisers's Alexion Pharmaceuticals position peaked at $1.15M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Wealthfront Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.